RxDoctor Payments Data

Bradley Boehm, DO

Urology · Alpena, MINPI 1225092554

Payments from drug & device makers

$4,045in general payments, 2019–2025

Across 222 payments — averaging $18.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$2K
  • Astellas Pharma US Inc$1K
  • Sumitomo Pharma America, Inc.$637
  • Urovant Sciences Inc$118
  • Johnson & Johnson$51
  • Boston Scientific$51
  • plus $306 from 14 others

What the payments were for

  • Food & beverage$3,68591%
  • Education$3619%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,045 in reported general payments places this provider in the 55th percentile of 400 urology providers in Michigan.

See all urology providers in Michigan

Medicare billing

Part B allowed, 2024
$309,031
Medicare patients
777
Services billed
8,755

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron315$239,800
GemtesaVibegron205$184,289
Mirabegron ErMirabegron45$36,918
Tamsulosin Hcl1,089$26,969
PremarinEstrogens, Conjugated42$17,620
Trimethoprim167$14,303
Finasteride685$12,633
Tolterodine Tartrate ErTolterodine Tartrate121$11,141
Solifenacin Succinate166$8,120
Bicalutamide25$7,033
Oxybutynin Chloride ErOxybutynin Chloride214$6,561
Fesoterodine Fumarate ErFesoterodine Fumarate58$6,142
Silodosin16$3,151
Testosterone40$3,111
Darifenacin ErDarifenacin Hydrobromide16$2,209

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$1,302$239,800315 claims
Sumitomo Pharma America, Inc.Gemtesa$637$184,289205 claims
PfizerPremarin$19$17,62042 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 400 urology providers in Michigan.

Other urology in Alpena

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →